KWM
BCRX icon

Kingsview Wealth Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Kingsview Wealth Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,427
Closed -$73.4K – 933
2023
Q2 		$73.4K Hold
10,427
– – ﹤0.01% 885
2023
Q1 		$87K Buy
10,427
+150
+1% +$1.44K ﹤0.01% 858
2022
Q4 		$118K Hold
10,277
– – 0.01% 815
2022
Q3 		$129K Buy
+10,277
New +$132K 0.01% 786

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Kingsview Wealth Management's BCRX Position: Q3 2023 in Review

Kingsview Wealth Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2023, closing a stake of 10,427 shares — an estimated $73.4K sold.

Kingsview Wealth Management first reported a position in BCRX in Q3 2022 and held it in 4 quarters. The position peaked at $129K in Q3 2022. 233 funds tracked by Wall St. Rank hold BCRX as of Q3 2023.

  • Kingsview Wealth Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Kingsview Wealth Management sold 10,427 BioCryst Pharmaceuticals shares in Q3 2023, an estimated $73.4K.
  • Kingsview Wealth Management first reported a position in BioCryst Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • Kingsview Wealth Management's BioCryst Pharmaceuticals position peaked at $129K in Q3 2022.
  • 233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2023.

Based on Kingsview Wealth Management's 13F filing for Q3 2023, filed 7 Nov 2023.